Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: A multi-institutional retrospective analysis

Giovenzio Genestreti, Marcello Tiseo, Hirotsugu Kenmotsu, Wakuda Kazushige, Monica Di Battista, Giovanna Cavallo, Federica Carloni, Alberto Bongiovanni, Marco Angelo Burgio, Claudia Casanova, Giulio Metro, Emanuela Scarpi, Taner Korkmaz, Seber Selcuk, Kurup Roopa, Raffaele Califano

Research output: Contribution to journalArticle

Abstract

Introduction Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide. Patients and Methods Records of all SCLC patients treated in 7 institutions between January 2007 and December 2011 were reviewed. The primary end point was overall survival from the time of rechallenge (OS-R); secondary end points were progression-free survival (PFS) and overall survival from the time of diagnosis (OS-D). Survival curves were calculated using the Kaplan-Meier method. Results Of the 2000 SCLC patients identified, 112 (5.6%) had sensitive disease treated with rechallenge platinum/etoposide; 65% were men with a median age of 64 years. At the time of diagnosis, 44% of patients had limited disease, 82% had an Eastern Cooperative Oncology Group performance status of 0 to 1. A median of 4 cycles of rechallenge was administered. Tumor response was 3% for complete response and 42% for partial response, 19% of patients maintained stable disease, 27% progressive disease, and 9% were not evaluable. Median PFS from the time of rechallenge was 5.5 months (95% confidence interval [CI], 4.4-6.3). Median OS-R and OS-D were 7.9 months (95% CI, 6.9-9.7) and 21.4 months (95% CI, 19.8-24.1), respectively. Subgroup analysis according to relapse-free interval (90-119 vs. 120-149 vs. > 150 days) did not show any statistically significant difference in PFS or OS-R. Conclusion The outcome for SL chemotherapy for SCLC is poor. Rechallenge platinum/etoposide is a reasonable option with potentially better outcomes than standard chemotherapy.

Original languageEnglish
Pages (from-to)e223-e228
JournalClinical Lung Cancer
Volume16
Issue number6
DOIs
Publication statusPublished - Nov 1 2015

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Platinum
Disease-Free Survival
Drug Therapy
Confidence Intervals
Survival
Recurrence

Keywords

  • Extended disease
  • Platinum sensitive
  • Rechallenge chemotherapy
  • SCLC
  • Second-line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge : A multi-institutional retrospective analysis. / Genestreti, Giovenzio; Tiseo, Marcello; Kenmotsu, Hirotsugu; Kazushige, Wakuda; Di Battista, Monica; Cavallo, Giovanna; Carloni, Federica; Bongiovanni, Alberto; Burgio, Marco Angelo; Casanova, Claudia; Metro, Giulio; Scarpi, Emanuela; Korkmaz, Taner; Selcuk, Seber; Roopa, Kurup; Califano, Raffaele.

In: Clinical Lung Cancer, Vol. 16, No. 6, 01.11.2015, p. e223-e228.

Research output: Contribution to journalArticle

Genestreti, G, Tiseo, M, Kenmotsu, H, Kazushige, W, Di Battista, M, Cavallo, G, Carloni, F, Bongiovanni, A, Burgio, MA, Casanova, C, Metro, G, Scarpi, E, Korkmaz, T, Selcuk, S, Roopa, K & Califano, R 2015, 'Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: A multi-institutional retrospective analysis', Clinical Lung Cancer, vol. 16, no. 6, pp. e223-e228. https://doi.org/10.1016/j.cllc.2015.04.006
Genestreti, Giovenzio ; Tiseo, Marcello ; Kenmotsu, Hirotsugu ; Kazushige, Wakuda ; Di Battista, Monica ; Cavallo, Giovanna ; Carloni, Federica ; Bongiovanni, Alberto ; Burgio, Marco Angelo ; Casanova, Claudia ; Metro, Giulio ; Scarpi, Emanuela ; Korkmaz, Taner ; Selcuk, Seber ; Roopa, Kurup ; Califano, Raffaele. / Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge : A multi-institutional retrospective analysis. In: Clinical Lung Cancer. 2015 ; Vol. 16, No. 6. pp. e223-e228.
@article{397a6676871d4b96ba2a01441e7388c4,
title = "Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge: A multi-institutional retrospective analysis",
abstract = "Introduction Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide. Patients and Methods Records of all SCLC patients treated in 7 institutions between January 2007 and December 2011 were reviewed. The primary end point was overall survival from the time of rechallenge (OS-R); secondary end points were progression-free survival (PFS) and overall survival from the time of diagnosis (OS-D). Survival curves were calculated using the Kaplan-Meier method. Results Of the 2000 SCLC patients identified, 112 (5.6{\%}) had sensitive disease treated with rechallenge platinum/etoposide; 65{\%} were men with a median age of 64 years. At the time of diagnosis, 44{\%} of patients had limited disease, 82{\%} had an Eastern Cooperative Oncology Group performance status of 0 to 1. A median of 4 cycles of rechallenge was administered. Tumor response was 3{\%} for complete response and 42{\%} for partial response, 19{\%} of patients maintained stable disease, 27{\%} progressive disease, and 9{\%} were not evaluable. Median PFS from the time of rechallenge was 5.5 months (95{\%} confidence interval [CI], 4.4-6.3). Median OS-R and OS-D were 7.9 months (95{\%} CI, 6.9-9.7) and 21.4 months (95{\%} CI, 19.8-24.1), respectively. Subgroup analysis according to relapse-free interval (90-119 vs. 120-149 vs. > 150 days) did not show any statistically significant difference in PFS or OS-R. Conclusion The outcome for SL chemotherapy for SCLC is poor. Rechallenge platinum/etoposide is a reasonable option with potentially better outcomes than standard chemotherapy.",
keywords = "Extended disease, Platinum sensitive, Rechallenge chemotherapy, SCLC, Second-line",
author = "Giovenzio Genestreti and Marcello Tiseo and Hirotsugu Kenmotsu and Wakuda Kazushige and {Di Battista}, Monica and Giovanna Cavallo and Federica Carloni and Alberto Bongiovanni and Burgio, {Marco Angelo} and Claudia Casanova and Giulio Metro and Emanuela Scarpi and Taner Korkmaz and Seber Selcuk and Kurup Roopa and Raffaele Califano",
year = "2015",
month = "11",
day = "1",
doi = "10.1016/j.cllc.2015.04.006",
language = "English",
volume = "16",
pages = "e223--e228",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Outcomes of platinum-sensitive small-cell lung cancer patients treated with platinum/etoposide rechallenge

T2 - A multi-institutional retrospective analysis

AU - Genestreti, Giovenzio

AU - Tiseo, Marcello

AU - Kenmotsu, Hirotsugu

AU - Kazushige, Wakuda

AU - Di Battista, Monica

AU - Cavallo, Giovanna

AU - Carloni, Federica

AU - Bongiovanni, Alberto

AU - Burgio, Marco Angelo

AU - Casanova, Claudia

AU - Metro, Giulio

AU - Scarpi, Emanuela

AU - Korkmaz, Taner

AU - Selcuk, Seber

AU - Roopa, Kurup

AU - Califano, Raffaele

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Introduction Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide. Patients and Methods Records of all SCLC patients treated in 7 institutions between January 2007 and December 2011 were reviewed. The primary end point was overall survival from the time of rechallenge (OS-R); secondary end points were progression-free survival (PFS) and overall survival from the time of diagnosis (OS-D). Survival curves were calculated using the Kaplan-Meier method. Results Of the 2000 SCLC patients identified, 112 (5.6%) had sensitive disease treated with rechallenge platinum/etoposide; 65% were men with a median age of 64 years. At the time of diagnosis, 44% of patients had limited disease, 82% had an Eastern Cooperative Oncology Group performance status of 0 to 1. A median of 4 cycles of rechallenge was administered. Tumor response was 3% for complete response and 42% for partial response, 19% of patients maintained stable disease, 27% progressive disease, and 9% were not evaluable. Median PFS from the time of rechallenge was 5.5 months (95% confidence interval [CI], 4.4-6.3). Median OS-R and OS-D were 7.9 months (95% CI, 6.9-9.7) and 21.4 months (95% CI, 19.8-24.1), respectively. Subgroup analysis according to relapse-free interval (90-119 vs. 120-149 vs. > 150 days) did not show any statistically significant difference in PFS or OS-R. Conclusion The outcome for SL chemotherapy for SCLC is poor. Rechallenge platinum/etoposide is a reasonable option with potentially better outcomes than standard chemotherapy.

AB - Introduction Patients with small-cell lung cancer (SCLC) that progresses after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients whose disease relapses/progresses > 90 days after FL platinum-based treatment are considered platinum-sensitive and could be rechallenged with a similar regimen. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients rechallenged with platinum/etoposide. Patients and Methods Records of all SCLC patients treated in 7 institutions between January 2007 and December 2011 were reviewed. The primary end point was overall survival from the time of rechallenge (OS-R); secondary end points were progression-free survival (PFS) and overall survival from the time of diagnosis (OS-D). Survival curves were calculated using the Kaplan-Meier method. Results Of the 2000 SCLC patients identified, 112 (5.6%) had sensitive disease treated with rechallenge platinum/etoposide; 65% were men with a median age of 64 years. At the time of diagnosis, 44% of patients had limited disease, 82% had an Eastern Cooperative Oncology Group performance status of 0 to 1. A median of 4 cycles of rechallenge was administered. Tumor response was 3% for complete response and 42% for partial response, 19% of patients maintained stable disease, 27% progressive disease, and 9% were not evaluable. Median PFS from the time of rechallenge was 5.5 months (95% confidence interval [CI], 4.4-6.3). Median OS-R and OS-D were 7.9 months (95% CI, 6.9-9.7) and 21.4 months (95% CI, 19.8-24.1), respectively. Subgroup analysis according to relapse-free interval (90-119 vs. 120-149 vs. > 150 days) did not show any statistically significant difference in PFS or OS-R. Conclusion The outcome for SL chemotherapy for SCLC is poor. Rechallenge platinum/etoposide is a reasonable option with potentially better outcomes than standard chemotherapy.

KW - Extended disease

KW - Platinum sensitive

KW - Rechallenge chemotherapy

KW - SCLC

KW - Second-line

UR - http://www.scopus.com/inward/record.url?scp=84944353160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944353160&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2015.04.006

DO - 10.1016/j.cllc.2015.04.006

M3 - Article

C2 - 25983005

AN - SCOPUS:84944353160

VL - 16

SP - e223-e228

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 6

ER -